Virtual Bioscience Pitch Event:
https://us02web.zoom.us/j/81770096645Meeting ID: 817 7009 6645
Innosphere Ventures: Bioscience Pitch Event
In this exclusive pitch event hosted by Innosphere Ventures, four high-growth, investment-ready science and technology-based companies will present in a virtual format on Wednesday, September 16th.
Investors will hear from companies currently raising capital that have secured early investment, including: Active Arm Supports, Laporte Immunotherapeutics, Validus Cellular Therapeutics, and ZeoMedical.
Please note that Innosphere is also holding a "Software & Hardware" pitch event on Thursday, Sept. 17th which requires a separate registration at:
Accredited investors may register below to attend. Please scroll down to read more information on each presenting company, including the option to view each company's executive summary.
Active Arm Supports
Supporting Your Recovery
Description: Active Arm Supports designs and manufactures tools to support effective rehabilitation of both orthopedic and neurological arm injuries. The company is passionate about building high-quality products that benefit recovery goals and promote functional outcomes in their clients.
On the web: www.ActiveArmSupports.com
Co-Founder: Jamie Rennick
Industries: Bioscience/Medical Device
Headquarters: Hygiene, CO
Intellectual Property: Active Arm Supports has exclusive licensing to 6 patents related to their products, which are extension enabled. The Co-Founder, Ron Krenzel, owns the patents.
Short CEO Bio: Jamie Rennick is a certified brain injury specialist and an occupational therapist of more than 13 years in rehabilitation therapy and Ron Krenzel is a long time businessperson and product innovator. Together they have Co-Founded Active Arm Supports.
Executive Summary: Click here to download.
___________________________________________________________________________________
Laporte Immunotherapeutics, Inc.
Active Immunotherapy for Preventing Respiratory Infections and Treating Viral Eye Infections
Description: Laporte Immunotherapeutics offers candidate immunomodulating drugs with better therapeutic utility, efficacy, and dosing profiles to treat viral infections of the eyes and respiratory system.
The technology is a liposomal Toll Like Receptor (TLR) agonist proven to stimulate key aspects of the immune system. The drug technology under development has shown broad utility. Animal model efficacy has been demonstrated for respiratory antiviral, ocular viral infections, and squamous cell carcinoma of the eye indications.
The leading use is as a nasal spray to prevent respiratory viral infection including SARS-CoV-2, animal studies are underway. Once efficacy is clinically demonstrated and regulatory approvals obtained, our lead respiratory viral indication represents a very large market opportunity encompassing 100s of millions of people worldwide on a yearly basis.
On the web: https://www.laporteimmuno.com/
CEO: Steve Tyrrell
Industries: Human pharmaceuticals and Animal Health Pharmaceuticals
Headquarters: Fort Collins, Colorado
Intellectual Property: Composition of matter patent was Issued (US 10,5 12,687) on Dec 24, 2019. Exclusive license from Colorado State University Research Foundation (CSURF). Currently obtaining protection in additional countries which are important markets for our pharma customers.
Short CEO Bio: Steve Tyrrell is the CEO of Laporte Immunotherapeutics and brings >25 years of entrepreneurial experience leading development and commercialization of regulated life science products. Mr. Tyrrell has a wealth of experience leading diverse teams, has taken three products through FDA clearance, and has won NIH grant and contract support. He has raised capital for 3 different companies, sold or licensed multiple technologies and is an active volunteer in Colorado Life Science startup communities.
Executive Summary: Click here to download.
___________________________________________________________________________________
Validus Cellular Therapeutics, Inc.
Treating Untreatable Infections
Description: For patients and doctors battling chronic resistant infections, Validus Cellular Therapeutics is developing VuropacinCT, a novel preclinical stage anti-infective therapy unlike current small molecule antibiotics which are susceptible to resistance and are limited accessing infections. VuropacinCT is a cell therapy to be given with standard of care antibiotic regimens to successfully treat of chronic infections.
On the web: https://validustherapeutics.com/
CEO: Ethan Mann, PhD, MBA
Industries: Bioscience
Headquarters: Aurora, Colorado
University: Validus' initial discovery started in the laboratory of Dr. Steven Dow, a renowned veterinary scientist at Colorado State University.
Intellectual Property: Validus has licensed the global rights to commercialization of the technology described in a PCT patent application filed Dec. 7, 2016: PCT/US2016/065392.
Short CEO Bio: Dr. Ethan Mann is Co-founder and CEO of Validus Cellular Therapeutics. Dr. Mann partnered with Dr. Dow following a successful tenure at Sharklet Technologies, Inc. where he was VP and COO. Dr. Mann is an experienced executive with a history fund raising both non-dilutive grants and equity, partner licensing, and international business activity, including acquisitions. Dr. Mann enjoys early stage startup, especially activities taking technologies from the laboratory to commercialized products. In addition to his PhD, Dr. Mann holds an MBA in finance from CU Denver.
Executive Summary: Click here to download.
___________________________________________________________________________________
ZeoMedical, LLC
Natures remedy for pain relief
Description: ZeoMedical has developed a multipurpose self-contained thermotherapy system that can provide relief of arthritis discomfort and chronic pain treatment. It is also an effective tool in an array of clinical and surgical applications.
CEO and founder: Michael Scata
Industries: Medical Devices, Healthcare
Headquarters: Longmont, Colorado
Intellectual Property: One hardware patent issued. One hardware patent pending. Two software applications preparing for submission.
Short CEO Bio: Michael Scata has managed three companies as President and/or CFO while directing the companies through liquidity events. He has extensive experience in startups, turning around troubled companies, and over 30 years’ experience in multiple federally regulated industries. He is a former Big-8 accounting firm audit manager and CPA.
Executive Summary: Click here to download.
